Tetsushi Sakuma

Dr. Tetsushi Sakuma

Division of Integrated Sciences for Life, Graduate School of Integrated Sciences for Life, Hiroshima University, Hiroshima 739-8526, Japan
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Cell Stem Cell
Verified
Journal Article
Closed access
KSKotaro Sasaki
Kotaro Sasaki
SYShihori Yokobayashi
Shihori Yokobayashi
TNTomonori Nakamura
Tomonori Nakamura
IOIkuhiro Okamoto
Ikuhiro Okamoto
YYYukihiro Yabuta
Yukihiro Yabuta
MSMitinori Saitou
Mitinori Saitou

1 January 2015 in Stem Cell Reports
Verified
Journal Article
Open access
HLHongmei Lisa Li
Hongmei Lisa Li
NFNaoko Fujimoto
Naoko Fujimoto
NSNoriko Sasakawa
Noriko Sasakawa
SSSaya Shirai
Saya Shirai
TOTokiko Ohkame
Tokiko Ohkame
AHAkitsu Hotta
Akitsu Hotta
Duchenne muscular dystrophy (DMD) is a severe muscle-degenerative disease caused by a mutation in the dystrophin gene. Genetic correction of patient-derived induced pluripotent stem cells (iPSCs) by TALENs or CRISPR-Cas9 holds promise for DMD gene therapy; however, the safety of such nuclease treatment must be determined. Using a unique k-mer database, we systematically identified a unique target region that reduces off-target sites. To restore the dystrophin protein, we performed three correction methods (exon skipping, frameshifting, and exon knockin) in DMD-patient-derived iPSCs, and found that exon knockin was the most effective approach. We further investigated the genomic integrity by karyotyping, copy number variation array, and exome sequencing to identify clones with a minimal mutation load. Finally, we differentiated the corrected iPSCs toward skeletal muscle cells and successfully detected the expression of full-length dystrophin protein. These results provide an important framework for developing iPSC-based gene therapy for genetic disorders using programmable nucleases.

20 November 2014 in Nature Communications
Verified
Journal Article
Open access
SNShota Nakade
Shota Nakade
TTTakuya Tsubota
Takuya Tsubota
YSYuto Sakane
Yuto Sakane
SKSatoshi Kume
Satoshi Kume
NSNaoaki Sakamoto
Naoaki Sakamoto
KSKen-Ichi T. Suzuki
Ken-Ichi T. Suzuki
Genome engineering using programmable nucleases enables homologous recombination (HR)-mediated gene knock-in. However, the labour used to construct targeting vectors containing homology arms and difficulties in inducing HR in some cell type and organisms represent technical hurdles for the application of HR-mediated knock-in technology. Here, we introduce an alternative strategy for gene knock-in using transcription activator-like effector nucleases (TALENs) and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (Cas9) mediated by microhomology-mediated end-joining, termed the PITCh (Precise Integration into Target Chromosome) system. TALEN-mediated PITCh, termed TAL-PITCh, enables efficient integration of exogenous donor DNA in human cells and animals, including silkworms and frogs. We further demonstrate that CRISPR/Cas9-mediated PITCh, termed CRIS-PITCh, can be applied in human cells without carrying the plasmid backbone sequence. Thus, our PITCh-ing strategies will be useful for a variety of applications, not only in cultured cells, but also in various organisms, including invertebrates and vertebrates.

17 December 2015 in Nature Protocols
Verified
Journal Article
Closed access
Tetsushi SakumaTetsushi Sakuma
Tetsushi Sakuma
SNShota Nakade
Shota Nakade
YSYuto Sakane
Yuto Sakane
KSKen-Ichi T Suzuki
Ken-Ichi T Suzuki
TYTakashi Yamamoto
Takashi Yamamoto

23 June 2014 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Tetsushi SakumaTetsushi Sakuma
Tetsushi Sakuma
ANAyami Nishikawa
Ayami Nishikawa
SKSatoshi Kume
Satoshi Kume
KCKazuaki Chayama
Kazuaki Chayama
TYTakashi Yamamoto
Takashi Yamamoto
CRISPR/Cas9-mediated genome editing is a next-generation strategy for genetic modifications, not only for single gene targeting, but also for multiple targeted mutagenesis. To make the most of the multiplexity of CRISPR/Cas9, we established a system for constructing all-in-one expression vectors containing multiple guide RNA expression cassettes and a Cas9 nuclease/nickase expression cassette. We further demonstrated successful examples of multiple targeting including chromosomal deletions in human cells using the all-in-one CRISPR/Cas9 vectors constructed with our novel system. Our system provides an efficient targeting strategy for multiplex genome/epigenome editing, simultaneous activation/repression of multiple genes, and beyond.

29 April 2015 in Genome Biology
Verified
Journal Article
Open access
PDF file
TATomomi Aida
Tomomi Aida
KCKeiho Chiyo
Keiho Chiyo
TUTakako Usami
Takako Usami
HIHarumi Ishikubo
Harumi Ishikubo
RIRisa Imahashi
Risa Imahashi
KTKohichi Tanaka
Kohichi Tanaka
Although the CRISPR/Cas system has enabled one-step generation of knockout mice, low success rates of cassette knock-in limit its application range. Here we show that cloning-free, direct nuclear delivery of Cas9 protein complex with chemically synthesized dual RNAs enables highly efficient target digestion, leading to generation of knock-in mice carrying a functional cassette with up to 50% efficiency, compared with just 10% by a commonly used method consisting of Cas9 mRNA and single guide RNA. Our cloning-free CRISPR/Cas system facilitates rapid one-step generation of cassette knock-in mice, accelerating functional genomic research by providing various in vivo genetic tools.